Graphical representation of the treatment and follow-up of the 349 patients. *High dose AraC (Leg2 I2A of MCP841 protocol)  started in view of ongoing infection (empyema). Allo HSCT, allogeneic HSCT; Ara C, cytarabine; BMT, bone marrow transplantation; CML, chronic myeloid leukemia; CVT, cerebral venous thrombosis; HDAraC, high-dose cytarabine; LFU, lost to follow-up.